Transcriptome studies have reported decreased levels of SOCS-3 in myeloid cells during COVID-19 [45], which could lead to an immunosuppressive response to IL-6-mediated STAT3 activation during COVID-19. This evidence concerns the gene IL6 and COVID-19.